Mirum Pharmaceuticals (FRA:08D) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:08D Mirum Pharmaceuticals Inc FRA:08D
52 GF Score
Price €78.04
GF Value €74.28
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Unearned Premiums?

Unearned Premiums only applies to insurance companies.

FRA:08D
52GF Score
Mirum Pharmaceuticals Inc FRA:08D
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mirum Pharmaceuticals (FRA:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €78.04 is trading 5.1% above its estimated GF Value™ of €74.28. GuruFocus considers Mirum Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:08D:

  • Unearned Premiums:
  • GF Value™: €74.28 vs. price of €78.04 (5.1% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FRA:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on therapies for rare and orphan liver diseases. Its lead product, Livmarli (maralixibat), is an orally administered ileal bile acid transporter inhibitor approved for cholestatic pruritus in patients with Alagille syndrome and for progressive familial intrahepatic cholestasis. The company also markets Cholbam (cholic acid) for bile acid synthesis disorders and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. Mirum is developing volixibat for adult cholestatic liver conditions, including primary sclerosing cholangitis and primary biliary cholangitis. Its customers are primarily specialty pharmacies, hospitals, and healthcare providers in the United States and Europe, where it sells directly and through distributors. Revenue comes mainly from product sales of its approved medicines, supplemented by licensing and collaboration arrangements.
52GF Score

Get the complete analysis for FRA:08D

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.04
Price
€74.28
GF Value